Bangstad H J, Kofoed-Enevoldsen A, Dahl-Jørgensen K, Hanssen K F
Aker Diabetes Research Centre, Aker University Hospital, Oslo, Norway.
Diabetologia. 1992 Dec;35(12):1165-9. doi: 10.1007/BF00401371.
We first compared glomerular charge selectivity index in two matched groups of Type 1 (insulin-dependent) diabetic patients with micro- and normoalbuminuria respectively, and secondly, investigated prospectively in a randomized clinical trial, the influence of improved metabolic control on selectivity index in diabetic patients with microalbuminuria. In Study 1, 27 patients with microalbuminuria (albumin excretion > or = 15 micrograms/min in at least two out of three overnight urine samples) were matched (age, diabetes duration, mean 1-year HbA1c, gender) with normoalbuminuria patients (n = 24), and in Study 2, 23 microalbuminuric patients were randomly allocated to either intensive (continuous subcutaneous insulin infusion) or conventional treatment. Glomerular charge selectivity index was measured as IgG/IgG4 selectivity index, i.e. total IgG/IgG4 clearance ratio in timed overnight urine samples. The microalbuminuric patients had a significantly reduced selectivity index compared to the normoalbuminuric patients: 1.20 (0.92-1.40) vs 1.68 (1.22-2.21), median and 95% confidence interval (p < 0.01). In Study 2, the HbA1c improved in the intensive-treatment group compared to the conventional-treatment group: at 2, 6 and 12 months the difference in mean percentage HbA1c between the groups was 1.1, 1.2 and 1.4, respectively (p < 0.01). A sharp 50% increment in IgG/IgG4 selectivity index was seen in the intensive-treatment group during the first 6 months (p < 0.05 compared to the conventional group). We conclude that adolescents and young adults in an early stage of diabetic nephropathy have reduced glomerular charge selectivity, which may be improved by reducing the mean blood glucose level.
我们首先比较了两组分别患有微量白蛋白尿和正常白蛋白尿的1型(胰岛素依赖型)糖尿病患者的肾小球电荷选择性指数,其次,在一项随机临床试验中进行前瞻性研究,观察改善代谢控制对微量白蛋白尿糖尿病患者选择性指数的影响。在研究1中,27例微量白蛋白尿患者(在三个夜间尿样中至少两个尿样的白蛋白排泄量≥15微克/分钟)与24例正常白蛋白尿患者进行匹配(年龄、糖尿病病程、平均1年糖化血红蛋白、性别)。在研究2中,23例微量白蛋白尿患者被随机分配至强化治疗组(持续皮下胰岛素输注)或传统治疗组。肾小球电荷选择性指数通过IgG/IgG4选择性指数来衡量,即定时夜间尿样中总IgG/IgG4清除率。与正常白蛋白尿患者相比,微量白蛋白尿患者的选择性指数显著降低:中位数及95%置信区间分别为1.20(0.92 - 1.40)和1.68(1.22 - 2.21)(p < 0.01)。在研究2中,强化治疗组的糖化血红蛋白较传统治疗组有所改善:在2个月、6个月和12个月时,两组间糖化血红蛋白平均百分比差异分别为1.1、1.2和1.4(p < 0.01)。强化治疗组在最初6个月内IgG/IgG4选择性指数急剧增加50%(与传统治疗组相比,p < 0.05)。我们得出结论,糖尿病肾病早期的青少年和年轻成年人肾小球电荷选择性降低,降低平均血糖水平可能会改善这一情况。